Oramed Pharmaceuticals (ORMP) Capital Expenditures (2011 - 2026)
Oramed Pharmaceuticals' (ORMP) quarterly Capital Expenditures came in at $5000.0 in Q1 2026, up 66.67% YoY from $3000.0 in Q1 2025, and up 150.0% on a QoQ basis from $2000.0 in Q4 2025.
Oramed Pharmaceuticals (ORMP) Capital Expenditures (2011 - 2026) Analysis & Trends
Oramed Pharmaceuticals (ORMP) has 15 years of Capital Expenditures data on file, last reported at $5000.0 in Q1 2026.
- Quarterly Capital Expenditures rose 66.67% year-over-year to $5000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11000.0 (down 42.11% YoY) and the FY2025 annual result came in at $9000.0, down 50.0% from the prior year.
- Capital Expenditures grew to $5000.0 in Q1 2026, from $2000.0 in the prior quarter.
- In the past five years, Capital Expenditures ranged from a high of $308000.0 in Q4 2022 to a low of $2000.0 in Q1 2024.
- A 5-year average of $52133.3 and a median of $11000.0 in 2024 frame the typical range for Capital Expenditures.
- The widest YoY moves for Capital Expenditures: up 323.4% in 2023, down 99.03% in 2023.
- Tracing ORMP's Capital Expenditures over 5 years: stood at $308000.0 in 2022, then slumped by 99.03% to $3000.0 in 2023, then surged by 266.67% to $11000.0 in 2024, then slumped by 81.82% to $2000.0 in 2025, then soared by 150.0% to $5000.0 in 2026.
- The last three Capital Expenditures figures came in at $5000.0 (Q1 2026), $2000.0 (Q4 2025), and $4000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Oramed Pharmaceuticals | 197.61 Mn | 197.61 Mn | - | 2,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2,000.00 |
| Jun 30, 2026 | 2,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Mar 31, 2026 | 5,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Dec 31, 2025 | 2,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Jun 30, 2025 | 4,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Mar 31, 2025 | 3,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Dec 31, 2024 | 11,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Sep 30, 2024 | 5,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Mar 31, 2024 | 2,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Dec 31, 2023 | 3,000.00 |
| Sep 30, 2023 | 32,000.00 |
| Sep 30, 2023 | 32,000.00 |